Author response to comment on "Phase 2 study of neoadjuvant durvalumab plus docetaxel, oxaliplatin, and S-1 with surgery and adjuvant durvalumab plus S-1 for resectable locally advanced gastric cancer".
作者信息
Kim Hyung-Don, Ryu Min-Hee, Kang Yoon-Koo
机构信息
Department of Oncology, Asan Medical Center, Seoul, Korea (the Republic of).
Department of Oncology, Asan Medical Center, Seoul, Korea (the Republic of)
出版信息
J Immunother Cancer. 2025 May 30;13(5):e012332. doi: 10.1136/jitc-2025-012332.
Abstract
摘要
相似文献
1
Author response to comment on "Phase 2 study of neoadjuvant durvalumab plus docetaxel, oxaliplatin, and S-1 with surgery and adjuvant durvalumab plus S-1 for resectable locally advanced gastric cancer".作者对关于“度伐利尤单抗联合多西他赛、奥沙利铂和S-1新辅助治疗并手术，以及度伐利尤单抗联合S-1辅助治疗可切除局部晚期胃癌的2期研究”评论的回复
J Immunother Cancer. 2025 May 30;13(5):e012332. doi: 10.1136/jitc-2025-012332.
2
Phase 2 study of neoadjuvant durvalumab plus docetaxel, oxaliplatin, and S-1 with surgery and adjuvant durvalumab plus S-1 for resectable locally advanced gastric cancer.度伐利尤单抗联合多西他赛、奥沙利铂和S-1用于可切除局部晚期胃癌新辅助治疗并手术，以及度伐利尤单抗联合S-1用于辅助治疗的2期研究
J Immunother Cancer. 2025 Mar 13;13(3):e010635. doi: 10.1136/jitc-2024-010635.
3
Comment on "Phase 2 study of neoadjuvant durvalumab plus docetaxel, oxaliplatin, and S-1 with surgery and adjuvant durvalumab plus S-1 for resectable locally advanced gastric cancer".关于“度伐利尤单抗联合多西他赛、奥沙利铂和S-1新辅助治疗并手术，以及度伐利尤单抗联合S-1辅助治疗可切除局部晚期胃癌的2期研究”的评论
J Immunother Cancer. 2025 Apr 15;13(4):e012221. doi: 10.1136/jitc-2025-012221.
4
MATTERHORN: phase III study of durvalumab plus FLOT chemotherapy in resectable gastric/gastroesophageal junction cancer.胃/胃食管结合部可切除癌患者中 durvalumab 联合 FLOT 化疗的 III 期研究（Matterhorn 研究）
Future Oncol. 2022 Jun;18(20):2465-2473. doi: 10.2217/fon-2022-0093. Epub 2022 May 10.
5
PRODIGY: A Phase III Study of Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 Versus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer.PRODIGY 研究：新辅助多西他赛、奥沙利铂和 S-1 联合手术与手术联合辅助 S-1 治疗可切除的晚期胃癌的 III 期研究。
J Clin Oncol. 2021 Sep 10;39(26):2903-2913. doi: 10.1200/JCO.20.02914. Epub 2021 Jun 16.
6
Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study.新辅助和辅助帕博利珠单抗联合化疗治疗局部晚期胃或胃食管交界癌（KEYNOTE-585）：多中心、双盲、随机 3 期研究的中期分析。
Lancet Oncol. 2024 Feb;25(2):212-224. doi: 10.1016/S1470-2045(23)00541-7. Epub 2023 Dec 19.
7
Neoadjuvant docetaxel, oxaliplatin and S-1 therapy for the patients with large type 3 or type 4 gastric cancer (OGSG1902): protocol of a multi-center, phase II study.新辅助多西紫杉醇、奥沙利铂和 S-1 治疗大型 3 或 4 型胃癌患者（OGSG1902）：一项多中心、Ⅱ期研究方案。
BMC Cancer. 2022 Jul 23;22(1):811. doi: 10.1186/s12885-022-09890-w.
8
[Safety and effectiveness of oxaliplatin combined with capecitabine or oxaliplatin combined with S-1 neoadjuvant chemotherapy in the treatment of advanced gastric cancer].奥沙利铂联合卡培他滨或奥沙利铂联合S-1新辅助化疗治疗进展期胃癌的安全性和有效性
Zhonghua Wei Chang Wai Ke Za Zhi. 2021 Feb 25;24(2):138-144. doi: 10.3760/cma.j.cn.441530-20200721-00433.
9
A phase 2 study of neoadjuvant chemotherapy plus durvalumab in resectable locally advanced head and neck squamous cell carcinoma.一项关于新辅助化疗联合度伐利尤单抗治疗可切除的局部晚期头颈部鳞状细胞癌的2期研究。
Cancer. 2023 Nov 1;129(21):3381-3389. doi: 10.1002/cncr.34930. Epub 2023 Jul 3.
10
Efficacy and safety of S-1 plus oxaliplatin combined with apatinib and camrelizumab as neoadjuvant therapy for patients with locally advanced gastric or gastroesophageal junction adenocarcinoma: a protocol for a single-arm phase II trial.S-1联合奥沙利铂、阿帕替尼和卡瑞利珠单抗作为局部晚期胃或胃食管交界腺癌患者新辅助治疗的疗效和安全性：一项单臂II期试验方案
Updates Surg. 2025 Jan;77(1):165-174. doi: 10.1007/s13304-024-02052-6. Epub 2024 Dec 30.
本文引用的文献
1
Phase 2 study of neoadjuvant durvalumab plus docetaxel, oxaliplatin, and S-1 with surgery and adjuvant durvalumab plus S-1 for resectable locally advanced gastric cancer.度伐利尤单抗联合多西他赛、奥沙利铂和S-1用于可切除局部晚期胃癌新辅助治疗并手术，以及度伐利尤单抗联合S-1用于辅助治疗的2期研究
J Immunother Cancer. 2025 Mar 13;13(3):e010635. doi: 10.1136/jitc-2024-010635.
2
Tremelimumab and durvalumab as neoadjuvant or non-operative management strategy of patients with microsatellite instability-high resectable gastric or gastroesophageal junction adenocarcinoma: the INFINITY study by GONO.曲美木单抗和度伐利尤单抗作为微卫星高度不稳定的可切除胃癌或胃食管交界腺癌患者的新辅助或非手术治疗策略：GONO的INFINITY研究
Ann Oncol. 2025 Mar;36(3):285-296. doi: 10.1016/j.annonc.2024.11.016. Epub 2024 Dec 3.
3
Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer: Updated Overall Survival Outcomes From Phase III PRODIGY.新辅助多西他赛、奥沙利铂和 S-1 加手术与可切除的晚期胃癌的辅助 S-1：来自 III 期 PRODIGY 的更新总生存结果。
J Clin Oncol. 2024 Sep 1;42(25):2961-2965. doi: 10.1200/JCO.23.02167. Epub 2024 Jul 12.
4
Adjuvant treatment for locally advanced gastric cancer: an Asian perspective.局部晚期胃癌的辅助治疗：亚洲视角
Gastric Cancer. 2024 May;27(3):439-450. doi: 10.1007/s10120-024-01484-8. Epub 2024 Mar 15.
5
Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study.新辅助和辅助帕博利珠单抗联合化疗治疗局部晚期胃或胃食管交界癌（KEYNOTE-585）：多中心、双盲、随机 3 期研究的中期分析。
Lancet Oncol. 2024 Feb;25(2):212-224. doi: 10.1016/S1470-2045(23)00541-7. Epub 2023 Dec 19.
6
Perioperative Atezolizumab Plus Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel for Resectable Esophagogastric Cancer: Interim Results From the Randomized, Multicenter, Phase II/III DANTE/IKF-s633 Trial.可切除食管胃结合部腺癌患者围手术期使用阿替利珠单抗联合氟尿嘧啶、亚叶酸钙、奥沙利铂和多西他赛治疗的随机、多中心、Ⅱ/Ⅲ期 DANTE/IKF-s633 试验的中期结果。
J Clin Oncol. 2024 Feb 1;42(4):410-420. doi: 10.1200/JCO.23.00975. Epub 2023 Nov 14.
7
DNA mismatch repair deficiency and outcomes of patients with locally advanced gastric cancer treated with preoperative docetaxel, oxaliplatin, and S-1 plus surgery and postoperative S-1 or surgery plus postoperative S-1: a sub-analysis of the phase 3 PRODIGY trial.术前多西他赛、奥沙利铂和 S-1 联合手术及术后 S-1 或手术加术后 S-1 治疗局部晚期胃癌患者的 DNA 错配修复缺陷与结局：III 期 PRODIGY 试验的亚分析。
Gastric Cancer. 2024 Jan;27(1):110-117. doi: 10.1007/s10120-023-01434-w. Epub 2023 Oct 27.
8
Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline.晚期胃食管癌的免疫治疗与靶向治疗：美国临床肿瘤学会指南
J Clin Oncol. 2023 Mar 1;41(7):1470-1491. doi: 10.1200/JCO.22.02331. Epub 2023 Jan 5.
9
Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair/Microsatellite Instability-High Gastric or Esophagogastric Junction Adenocarcinoma: The GERCOR NEONIPIGA Phase II Study.新辅助纳武利尤单抗联合伊匹单抗和辅助纳武利尤单抗治疗局部缺陷错配修复/微卫星不稳定高型胃或胃食管结合部腺癌：GERCOR NEONIPIGA Ⅱ期研究。
J Clin Oncol. 2023 Jan 10;41(2):255-265. doi: 10.1200/JCO.22.00686. Epub 2022 Aug 15.
10
Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.胃癌：ESMO 诊断、治疗及随访临床实践指南
Ann Oncol. 2022 Oct;33(10):1005-1020. doi: 10.1016/j.annonc.2022.07.004. Epub 2022 Jul 29.
Zotero 插件